



## Seroprevalence of Human Herpesvirus Type 8 (HHV-8) Among People Living With HIV Attending Jigawa State General Hospital

Nazir A Yahaya<sup>1</sup>, and Taysir Ramadan Hafiz<sup>2</sup>

<sup>1</sup>Medical Officer, Babura General Hospital, Jigawa State

<sup>2</sup>Department of Medical Microbiology and Immunology, Al-Azhar University and Bayero University Kano  
[dr.taysiralassuty@gmail.com](mailto:dr.taysiralassuty@gmail.com)

**Abstract:** Human Herpes virus type 8 is among the frequent opportunistic infections among individuals infected with human immunodeficiency virus (HIV) and may result in severe morbidity and mortality among this group of patients. It is known to be the causative agent of Kaposi's sarcoma (KS), as well as other malignancies such as primary effusion lymphoma and multi centric Castleman's disease. It is one of seven currently known human cancer viruses, or onco viruses. This study investigate the prevalence of HHV8 antigen among PLWHA as well as its correlations with the patients CD4 counts and Viral loads. This cross-sectional study involved 182 blood sample collected from HIV Seropositive individuals attending antiretroviral therapy clinic (ART), Babura General Hospital, Jigawa State, Nigeria, these Sample were analysed for HHV-8 antigen using Enzyme linked Immunosorbent assay and CD4 cell Count. socio-demographic information such as age, gender, marital status was obtained from patient folder. Of the 182 subject studied, 6(3.3%) were tested positive for HHV-8 Antigen. All subjects (100%) who were HHV8 Positive have low CD4 Count and high HIV Viral loads. There was statistically significant difference between HHV8 and respondents CD4 Count ( $p = 0.001$ ) and also respondents compliance to Clinic visit ( $p = 0.000$ ). However, no association observed between HHV8 and respondents Gender and their Age. This study shows that individuals with higher CD4+ counts has zero prevalence of HHV8 infection and hence have low risk of developing complication from the virus, it also indicate that HHV8 was higher among HIV patient with lower CD4 Counts and high HIV Viral load.

[Nazir A Yahaya, and Taysir Ramadan Hafiz. **Seroprevalence of Human Herpesvirus Type 8 (HHV-8) Among People Living With HIV Attending Jigawa State General Hospital.** *Nat Sci* 2020;18(3):120-124]. ISSN 1545-0740 (print); ISSN 2375-7167 (online). <http://www.sciencepub.net/nature>. 14. doi:[10.7537/marsnsj180320.14](https://doi.org/10.7537/marsnsj180320.14).

**Keywords:** HHV8, HIV/AIDS; Seroprevalence; Human; Herpesvirus

### 1. Introduction

Human herpesvirus 8 (HHV-8) is one of the member of the gamma- herpesvirus family. Also known as Kaposi's sarcoma-associated herpesvirus (KSHV), it is known to be the causative agent of Kaposi's sarcoma (KS), as well as other malignancies such as primary effusion lymphoma and multicentric Castleman's disease (Casarman *et al*,1995; Zhang and Wang, 2017; Butler *et al*, 2011; Shivane *et al.*, 2018; Guerrero *et al.* 2019).

It has a diameter of 140 nm and a genome of between approximately 165 kb (Brooks *et al.*, 2013) and 170 kb (Russo *et al.*, 1996). double stranded linear DNA and icosahedral capsid envelope (Viejo-Borbolla *et al.*, 2003). It is covered by a tegument containing protein, and closed during budding of the cell. The membrane is derived from outer envelope of lipid membrane from various host and specific virus glycoprotein (Oktafiani *et al.*,2018)

It is also estimated to be 1% to 5% in the general U.S. population<sup>1</sup>, compared with 10% to 20% in

certain Mediterranean countries and 30% to 80% in parts of sub-Saharan Africa. (Aids Info, 2018)

### 2. Materials and Method

#### 2.1 Study Area/Site

This study was carried out in the out-patient and in-patient attending ART clinic of Baburageneral Hospital from march 2018-september 2018, with age range from 14years and above. A total of 182 samples were tested to determine respondents CD4 Count from cyflow and HHV8 antigen using ELISA from SUNLONGBIOTECH. The cut-off value for the serum was obtained by averaging the two negative controls wells reading and adding 0.15 to it, Positive and negative judgment were obtained by comparing the optical density OD for each well gotten with cut off.

The critical value (CUT OFF) calculation: critical value = the average value of negative control + 0.15  
 Negative judgment: if the OD value < CUT OFF, the sample is HHV8 negative. Positive judgment: if the OD value  $\geq$  CUT OFF, the sample is HHV8 positive.

Test effectiveness: the average value of positive control  $\geq 1.00$  and the average value of negative control  $\leq 0.10$ .

### 3. Results

In this study, we examined and tested the sera of 182 HIV infected patients Mean age was  $34.38 \pm 8.6$  with a range of 14–60 years. Male were 56(30.8%) while Female were 126 (69.2%). 6people (3.3%) were tested Positive for HHV8 antigen, among HHV8 Positive individual, one (1) is male (0.55%) and 5 were Female (2.75%). The sex composition in this study is that of 70 Females for 100 males giving a male to female ratio of 1: 2.3, as in Table 4.1.1 All of the respondents with positive HHV8 Antigenaemia have low CD4 Count.

In respondents with CD4 0 – 200: 6(11.5%) were HHV8 Positive, 46(88.5%) were HHV8 Negative. Respondents with CD4 Counts 201 – 499 and > 500 were all found to be 100% HHV8 Negative. Table 4.4 shows Those with positive HHV8 antigenaemia were found to be within the range of CD4 Count 0 – 200 and those with low CD4 Count were found to have high HIV Viral load. All HIV/HHV8 Co – infected patients have poor compliance to clinic visit. Good and Fair Compliance were seen in HHV8 negative respondents while Poor compliance were seen in 100% of HHV8 Positive respondents, no significant difference observed between HHV8 and respondents gender (Fisher exact  $p = 0.6689$ ), age group (Fisher exact  $P = 0.779$ ) and their Marital Status (Fisher exact  $p = 0.467$ ).

**Table 4.1** Socio demographic characteristics and distribution of HHV8

Variables	Observation	No. tested	No. HHV8 Positive/%	P - value
Age in years (mean $\pm$ SD)	34.38 $\pm$ 8.6	182	NA	
Gender	Male	56	1(1.8%)	0.668
	Female	126	5(4.0%)	
Age range (years)	10 – 20	9	0(0%)	0.779
	21 – 30	65	3(4.6%)	
	31 – 40	64	1(1.6%)	
	41 – 50 51 – 60	40 4	2(5%) 0(0%)	
Marital Status	Married	20	1(5.0%)	0.467
	Single	99	2(2.0%)	
	Divorced	58	3(5.2%)	
	Widow/Widower	5	0(0%)	
	Total	182	6(3.3%)	

**Table 4.2: Seroprevalence of HHV8 Antigen Among Plwaha**

Group	No. of Subject	Percentage
HIV Mono – infected	176	96.7
HIV/HHV8 Co – infected	6	3.3

PLWHA = people living with HIV/AIDS

**Table 4.3: Relationship Between CD4 Count and HHV-8**

CD4 Count	HHV8 Positive	HHV8 Negative	Total
0 – 200	6	46	52
201 – 499	0	82	82
>500	0	48	48

$P < 0.05$   $\chi^2 = 15.511$ ,  $df = 2$ , Fisher exact  $P = 0.001(S)$

**Table 4.4 Relationship Between CD4 Count, HIV Viral Load and HHV8 Positive Samples**

HHV8 Positive Sample	CD4 Count	HIV Viral Load
1	200	4895
2	92	10351
3	80	4380
4	199	4450
5	34	509721
6	200	2888

$p > 0.05$   $r(4) = -0.704(S)$

**Table 4.5:** Relationship between Compliance to Clinic Visit and HHV8 antigenaemia

Clinic Compliance	HHV8 Positive	HHV8 Negative	Total
Good Compliance	0	83	83
Fair Compliance	0	63	63
Poor Compliance	6	30	36

$P < 0.05$   $X^2 = 25.163$ ,  $df = 2$ , Fisher exact  $P = 0.000(S)$




Figure (1)

#### 4. Discussion

The sample consisted of 182 Patients from ART Clinic Babura General Hospital with age range 14–60 years and mean age of  $34.38 \pm 8.6$  years. Majority of the respondents (70.9%) fall within the age group of 21 - 40 this does not correspond to study by Agwu *et al.* (2011) in Edo state and in Jos by Zakari *et al.* (2012). The differences could be due to age distribution pattern of the study areas. Conversely it tall with a study done in Indonesia by Oktafani *et al.* (2018).

The sex composition in this study is that of 70 Females for 100 males giving a male to female ratio of 1: 2.3. This is not a case in study conducted in Tanzania (2.75:1) by Mwakigonja *et al.*, 2008 and 1.64:1 In Indonesia by Oktafani *et al.* (2018). These differences could be due to age group selection of respondents, environmental factors as well as socio-cultural differences between the various study areas.

Majority of respondents with positive HHV8 were Females This is not a case in study conducted in Tanzania by Mwakigonja *et al.* (2008) in which those with positive HHV8 Antigenaemia were mostly Males, the differences in gender could possibly result from more women attend the Clinic as compare to their Males counterpart as they are mostly Vagrant attending ART Clinic elsewhere, this also explains

why more women are recruited for the study. No significant difference observed between HHV8 and respondents gender (Fisher exact  $p = 0.6689$ ), age group (Fisher exact  $P = 0.779$ ) and their Marrital Status.

(Fisher exact  $p = 0.467$ ). This findings exactly confirmed the findings of Oktafani *et al.*, (2018) in Indonesia (age;  $p = 0.5$ , gender;  $p = 0.78$  and Marrital status;  $p = 0.6$ ) but not in keeping with that of Butler *et al.* (2011) among Ugandan HIV Populations.

The overall Seroprevalence of HHV8 in HIV positive individuals in this study is found to be 3.3%. This is not in keeping with previous studies 87% by Agwu *et al.* (2011) South- South Nigeria, 70% by Wonje *et al.* (2013) in Cameroon, 31.2% by Zhang *et al.* (2012) in Xinjiang, China and 14.5% in East Java, Indonesia by Oktafani *et al.* (2018). These differences could be due to differences in the nature of the study in which this study was conducted on antigen detection while that of previous study were on anti body detection. Majority of the respondents might have antibody against the HHV8 virus because they might have got the infection at one point or the other in their life time and might get cured of the Disease when they are commence on HAART, leaving only traces of antibody in their system which antigen detection procedure may not pick. 3.3% of the respondents are

those having the actual infection at a time of the study. Conversely the result Obtained was in keeping with that found in United State of America 1 – 5% by Aids Info, 2018.

All of the respondents with positive HHV8 Antigenaemia have low CD4 Count, Positive relationship was also identified between them ( $p = 0.001$ ) This findings tally with study conducted in China by Jiayan Li *et al.* (2017) ( $p = 0.0004$ ). However no differences in mean CD4+ cell counts according to HHV8 status were found according to Braun *et al.* (2014).

All HIV/HHV8 Co–infected patients have poor compliance to clinic visit. There is significant difference between HHV8 and compliance to clinic visit and follow- up ( $P < 0.05$ ),  $X^2 = 25.163$ , Fisher exact  $P = 0.000(S)$ .

Coincidentally, some of the Patients with low CD4 Count  $<200$  were found to have clinical evidence KSHV, Presented with hyper pigmented maculopapular skin lesion involving skin and Oral mucosa which is in keeping with clinical evidence of Kaposi sarcoma lesion (Fig 1), this is in line with finding of AIDSinfo, (2016). Also significant linear correlation were observed between respondents sample with positive HHV8 Antigenaemia and their respective CD4 Counts and Viral loads.  $r(4) = -0.704(S)$ , this is also in line with study conducted by Jiayan Li *et al.* (2017).

## 5. Conclusion

From the results obtained from this study it could be concluded that HHV8 was higher among HIV patient with lower CD4 Counts and high HIV Viral load. The evaluation of CD4+ counts of the HIV patients shows that individuals with higher CD4+ counts has zero prevalence of HHV8 infection and hence have low risk of developing complication from the virus. In particular, low CD4 Count and high HIV Viral load seems to be the major culprit in developing HHV8 Infection and its complications.

## 6. Recommendation

In view of the findings of this study, the following are recommended:

1. There is need for government and other development partners to support interventional programs specifically targeted toward PLWHA in term of treatment compliance and Clinic visit.
2. Government and development partners should support operational research to determine the possible and effective ways and treatment strategies in HHV8/HIV Co infections and their Complications.
3. Government and development partners should strengthen efforts towards public awareness of HHV8/HIV/AIDS Co infections prevention and

control especially using the electronic media, Religious and traditional leaders.

## Reference

1. Agwu, B.U., Eze, E.U., Onunu, A.N. (2011). Comparison of Prevalence of Kaposi's Sarcoma in HHV8+ and HHV8-HIV Infected Patients in South-South Nigeria. *Global Journal of Health Science*, 3:1.
2. AIDSinfo (2016). Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV- Exposed and HIV-Infected Children. Retrieved October 22<sup>nd</sup>,2018 from [https://aidsinfo.nih.gov/guidelines/html/5/paediatric-opportunistic\\_infection/407/human-herpesvirus-8-disease](https://aidsinfo.nih.gov/guidelines/html/5/paediatric-opportunistic_infection/407/human-herpesvirus-8-disease).
3. AIDSinfo (2018). Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Retrieved March 15, 2018 From <https://aidsinfo.nih.gov/apps>.
4. Braun A., Dominique L., Kamarachev J. And Günthard H,F (2014) New Onset of Kaposi Sarcoma in a Human Immunodeficiency Virus-1-Infected Homosexual Man, Despite Early Antiretroviral Treatment, Sustained Viral Suppression, and Immune Restoration, *Open Forum Infect Dis. Mar*; 1(1):005.
5. Brooks, G.F., Carol, K.C., Butel, J.S., Morse, S.A., Mietzner, T.A. (2013). Jawetz, Melnick, & Adelberg's Medical Microbiology: Twenty-six Edition ed. USA: McGraw Hill, p.467-488.
6. Butler L.M., Were W.A., Balinandi S, Downing R, Dollar S, Neilands T.B., Gupta S, Rutherford G.W and Mermin J. (2011). Human Herpesvirus 8 Infection in Children and Adults in a Population-based Study in Rural Uganda. *The Journal of Infectious Diseases*, 203:625–634.
7. Carlo Guerrero, Tania Jain, and Katalin Kelemen (2019) HHV-8-Associated Lymph proliferative Disorders and Pathogenesis in an HIV-Positive Patient. Case Reports in Hematology, Volume 2019, Article ID 4536157, 6 pages, <https://doi.org/10.1155/2019/4536157>
8. Casper, C. (2006). Human Herpesvirus-8, Kaposi Sarcoma, and AIDS associated Neoplasms. Retrieved December 31, 2017, From <http://hivinsite.ucsf.edu/InSite?page=kb-00&doc=kb-06-02-01>.
9. Cesarman E, chang Y, Moore P.S., Said J.W. and Knowles D.M (1995) Kaposi's sarcoma – associated herpesvirus – like dna sequences in aids – related body – cavity- based lymphomas. *The new England journal of medicine*,332:1186-1191.

10. Corey Casper (2006). Human Herpesvirus-8, Kaposi Sarcoma, and AIDS associated Neoplasms. Retrieved December 31, 2017, From [http://hivinsite.ucsf.edu/InSite?page=kb-00 & doc=kb-06-02-01](http://hivinsite.ucsf.edu/InSite?page=kb-00&doc=kb-06-02-01).
11. Jiayan Li, Song J., Tan G., Wang J., Zhou Z. and Wu X. ( 2017) High Seroprevalence of Human Herpesvirus 8 Infection in HIV-positive Homosexual Men in Jiangsu Province, China, *Current HIV Research*15:4.
12. Mwakigonja A.R., Pyakurel P, Park F, Lema L.K., Kaaya E.E., and Bibefeld P (2008). Human Herpesvirus 8 Sero-detection and HIV association in KS and non- KS tumour and non neoplastic conditions: *Infectious agent and Cancer* 3:10.
13. Oktafiani D, Megasari N.L.A., Fitriana E, Nasonudin, Lusida M.I., Soetjipto (2018) detection of human herpesvirus-8 antigen in hiv-infected patients in east java, indonesia: *Afr., J. Infect. Dis.*12 (2): 43-46.
14. Russo, J.J., Bohenzky, R.A., Chien, M-C., Chen, J., Yan, M., Maddalena, D., Parry, J.P., Peruzzi, D., Edelman, I.S., Chang, Y., and Moore, P.S. (1996). Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). *Proceeding of the National Academy of Sciences of the United States of America.* 93 (25):14862–14867.
15. Shivane A., A. Pearce, N. Khatib, and M. E. F. Smith, (2018) “EBV+ HHV-8+ multicentric castleman disease with plasmablastic aggregates in an HIV+ man: an evolving clinicopathologic entity,” *International Journal of Surgical Pathology*, vol. 26, no. 4, pp. 338–341.
16. Thermo Fisher Scientific. (2007). Plasma and Serum Preparation, retrieved from <http://www.thermofisher.com/ng/en/home/references/protocols/cell-and-tissueanalysis/elisa-protocol/elisa-sample-preparation-protocols/plasma-and-serum-preparation.html>.
17. Viejo-Borbolla, A., Ottinger, M., Schulz, T.F. (2003). Human herpesvirus 8: Biology and role in the pathogenesis of Kaposi’s sarcoma and other AIDS-related malignancies. *Current HIV/AIDS Reports.* 5:169–175.
18. Wonje, C.M., Viswanath, R., Sherwin, L., Owen,W., Bih, A., and Indira, K.H. (2013). Seroprevalence of Human Herpesvirus-8 in HIV-1 Infected and Uninfected Individuals in Cameroon. *mdpi journal* 5:2253-2259.
19. Zakari, H., Nimzing, L., Agabi, Y. A., Amagam, P. and Dashe M. M. (2012). seroprevalence of human herpes virus 8 (hhv8) infection among commercial sex workers in Jos. *Bayero Journal of Pure and Applied Sciences*, 5(1): 159 – 162.
20. Zhang, T., Wang, L. (2017) Epidemiology of Kaposi's sarcoma-associated herpesvirus in Asia: Challenges and opportunities. *Journal of Medical Virology* 89: 563 – 570.

2/2/2020